Article Information
vol. 24 no. 135 58-64
PubMed
Published By
Print ISSN
Online ISSN
History
- Received November 21, 2014
- Accepted January 5, 2015
- Published online February 28, 2015.
Copyright & Usage
Copyright ©ERS 2015. ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
Author Information
- 1National Reference Centre for Rare Pulmonary Diseases, Dept of Respiratory Medicine, Louis Pradel Hospital, Claude Bernard Lyon 1 University, UMR 754, Lyon, France
- 2National Heart and Lung Institute, Imperial College, London, UK
- 3NIHR Respiratory Biomedical Research Unit, Royal Brompton Hospital, London, UK
- Vincent Cottin, Hôpital Louis Pradel, Service de Pneumologie, 28 Avenue Doyen Lepine, 69677 Lyon Cedex, France. E-mail: vincent.cottin{at}chu-lyon.fr
Article usage
Altmetrics
Vol 24 Issue 135
Table of Contents
Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
Jump To
- Article
- Abstract
- Abstract
- Introduction
- Overview of the pirfenidone clinical development programme
- Pirfenidone treatment-emergent adverse events in the CAPACITY and ASCEND trials
- Pirfenidone safety and tolerability in long-term observational studies
- Single-centre real-world experience with pirfenidone
- Managing pirfenidone-related adverse effects in clinical practice
- Treatment initiation in IPF
- Treatment goals
- Treatment adherence with pirfenidone
- Timing of adverse events with pirfenidone
- Prevention and management of gastrointestinal side-effects
- Prevention and management of rash or photosensitivity
- Conclusion
- Acknowledgements
- Footnotes
- References
- Figures & Data
- Info & Metrics